Has India's 1st Dengue Vaccine Reached the 70% Enrollment Milestone in Phase III Trials?
Click to start listening
Synopsis
India's first dengue vaccine, DengiAll, has reached a crucial milestone in its Phase III clinical trial with a remarkable 70% enrollment rate. This indigenous vaccine, developed by Panacea Biotec, aims to tackle all four dengue virus serotypes and is nearing completion. Discover the details of this significant health advancement!
Key Takeaways
- DengiAll is India's first tetravalent dengue vaccine.
- It has reached 70% enrollment in its Phase III trial.
- The trial includes over 10,000 participants.
- The vaccine is developed by Panacea Biotec.
- Initial trials show no safety concerns.
New Delhi, Aug 1 (NationPress) The Phase III clinical trial for India's first dengue vaccine has successfully enrolled 70 percent of its participants, as announced by Union Minister of State for Health, Prataprao Jadhav, during a parliamentary session on Friday.
In a written response to the Lok Sabha, Jadhav provided insights into the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll.
"The trial is set to include over 10,000 participants, and we have completed more than 70 percent of the enrollment phase," Jadhav stated. The trial is expected to conclude by October.
"This trial is being conducted at 20 locations throughout India, with each site operating on a budget of approximately Rs 1.3 to 1.5 crore," he added.
The homegrown tetravalent dengue vaccine, DengiAll, is under development by Panacea Biotec through a licensing agreement with the National Institutes of Health (NIH). This vaccine targets all four subtypes of the dengue virus and has shown encouraging results in previous clinical trials.
According to data from the National Centre for Disease Control (NCDC), a total of 573,563 laboratory-confirmed dengue cases were documented in 2024.
“As per the Indian Council of Medical Research (ICMR), all four serotypes of the dengue virus—DENV-1, DENV-2, DENV-3, and DENV-4—are active and circulating in India,” Jadhav remarked.
It is possible for multiple serotypes to exist in the same area and even infect the same individual simultaneously.
“Therefore, participants in the ICMR vaccine trial have been recruited from various regions where these four serotypes are prevalent to assess the vaccine's effectiveness against all of them,” he added.
DengiAll is being developed by Panacea Biotec under a licensing agreement with the NIH, the principal U.S. federal agency for biomedical research. Initial findings indicate no safety issues associated with this one-shot vaccine aimed at combating the mosquito-borne viral disease.
Referring to ICMR, Jadhav pointed out that there are currently no specific antiviral treatments or approved vaccines for dengue.
The government has also established national guidelines for the treatment and management of dengue cases, highlighting the need for hospital preparedness in handling these cases, the minister noted.
Point of View
The progress of the DengiAll vaccine offers a beacon of hope. With over 70% participant enrollment, the Phase III trial signifies a critical step toward innovative health solutions. The collaboration between Panacea Biotec and the NIH exemplifies India's commitment to combating infectious diseases. This vaccine could change the landscape of dengue prevention in the country.
NationPress
08/10/2025
Frequently Asked Questions
What is DengiAll?
DengiAll is India's first indigenous tetravalent dengue vaccine being developed to protect against all four dengue virus serotypes.
When is the trial expected to be completed?
The Phase III clinical trial for DengiAll is anticipated to conclude by October.
How many participants are involved in the trial?
The trial aims to enroll over 10,000 participants, with 70% already enrolled.
Who is developing the DengiAll vaccine?
The vaccine is being developed by Panacea Biotec under a licensing agreement with the National Institutes of Health (NIH).
Are there any safety concerns regarding DengiAll?
Initial results indicate no safety issues associated with the DengiAll vaccine.
